MA
ARQT icon

MYDA Advisors’s Arcutis Biotherapeutics ARQT Stock Holding History

MYDA Advisors’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.65M Sell
240,000
-25,000
-9% -$638K 1.33% 31
2025
Q4 		$7.7M Sell
265,000
-205,000
-44% -$5.25M 2.17% 15
2025
Q3 		$8.86M Buy
470,000
+100,000
+27% +$1.58M 2.66% 9
2025
Q2 		$5.19M Buy
370,000
+80,000
+28% +$1.12M 1.46% 33
2025
Q1 		$4.54M Buy
290,000
+90,000
+45% +$1.27M 1.61% 36
2024
Q4 		$2.79M Buy
200,000
+80,000
+67% +$877K 0.8% 42
2024
Q3 		$1.12M Buy
120,000
+45,000
+60% +$444K 0.32% 76
2024
Q2 		$698K Hold
75,000
– – 0.21% 82
2024
Q1 		$743K Sell
75,000
-145,000
-66% -$1.08M 0.26% 77
2023
Q4 		$711K Buy
+220,000
New +$598K 0.3% 59

Other funds holding ARQT

SCM
Suvretta Capital Management New York $3.69B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $8.16B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $22.9B AUM 115.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return